Market Overview

Morgan Stanley Hopes for Some Retail Therapy for Humana

Share:
Related HUM
Healthways Up 100% In The Last Month, But UBS Says Sell
Argus Talks Humana-Aetna Deal Uncertainty, Raises EPS Estimates For Humana
Wall Street Breakfast: Week Of Economic Data Up Next (Seeking Alpha)

In a report published Thursday, Morgan Stanley analyst Andrew Schenker reiterated an Equal-Weight rating on Humana (NYSE: HUM).

In the report, Morgan Stanley noted, “HUM maintained its 2014 EPS outlook of $7.25 to $7.75, but increased its Medicare Advantage, Part D, and commercial individual enrollment outlook on the heels of 4Q. We have lowered our FY14 EPS by $0.05 to $7.70, which reflects higher revenue from new lives, but a lower overall pre-tax margin.”

Humana closed on Wednesday at $95.71.

Latest Ratings for HUM

DateFirmActionFromTo
Aug 2016Credit SuisseMaintainsNeutral
Aug 2016JefferiesMaintainsBuy
Aug 2016BarclaysMaintainsEqual-weight

View More Analyst Ratings for HUM
View the Latest Analyst Ratings

Posted-In: Andrew Schenker Morgan StanleyAnalyst Color Reiteration Analyst Ratings

 

Related Articles (HUM)

View Comments and Join the Discussion!